The estimated Net Worth of Rudolf Kwan is at least $1.53 Million dollars as of 3 August 2022. Rudolf Kwan owns over 17,500 units of Athenex Inc stock worth over $59,062 and over the last 7 years he sold ATNX stock worth over $0. In addition, he makes $1,473,850 as Chief Medical Officer at Athenex Inc.
Rudolf has made over 13 trades of the Athenex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 17,500 units of ATNX stock worth $3,500 on 3 August 2022.
The largest trade he's ever made was exercising 24,000 units of Athenex Inc stock on 7 May 2021 worth over $109,200. On average, Rudolf trades about 1,990 units every 32 days since 2017. As of 3 August 2022 he still owns at least 295,312 units of Athenex Inc stock.
You can see the complete history of Rudolf Kwan stock trades at the bottom of the page.
Dr. Rudolf Kwan serves as Chief Medical Officer of the Company. Dr. Kwan was engaged on a consultant basis. Dr. Kwan has over 20 years of experience in the pharmaceutical industry in global clinical development and operations. Before joining us, he served dual roles at Schering-Plough as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development (“CNS”). In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific for Schering-Plough. As Vice President of Global CNS he was responsible for the clinical development of all Schering-Plough’s central nervous system drugs, globally, where his achievements included overseeing development and execution of a bioequivalence registration strategy for a new formulation of Temodol for glioblastoma, which led to a simultaneous global registration. He also designed and executed multiple global development programs. He held similar positions at Chiron Corporation and was at Smith-Kline Beecham. Dr. Kwan obtained his medical degree (MBBS) from the University of Hong Kong, and received subsequent training at the University of Wales and is a member of the Royal College of Physicians in the United Kingdom.
As the Chief Medical Officer of Athenex Inc, the total compensation of Rudolf Kwan at Athenex Inc is $1,473,850. There are 1 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.
Rudolf Kwan is 67, he's been the Chief Medical Officer of Athenex Inc since 2014. There are 7 older and 10 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
Rudolf's mailing address filed with the SEC is C/O ATHENEX, INC.,, 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang, and Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Athenex Inc executives and other stock owners filed with the SEC include: